Orexo announced the launch of Zubsolv (buprenorphine, naloxone) sublingual tablets in a new 8.6mg/2.1mg dosage strength following a supplemental New Drug Application submission in December 2013.

Zubsolv combines buprenorphine, an opioid (partial agonist-antagonist), and naloxone, an opioid antagonist. It is a CIII controlled substance approved as maintenance treatment of opioid dependence, as part of a complete treatment plan to include counseling and psychosocial support.

RELATED: New Zubsolv Dosage Strength Coming Soon

Zubsolv is already available as 1.4mg/0.36mg and 5.7mg/1.4mg strengths in 3X10 cartons. The new 8.6mg/2.1mg strength is also available as 3X10 tablets per carton.

For more information call (855) 713-4110 or visit Zubsolv.com.